Matinas BioPharma Holdings, Inc. has taken a significant step by granting stock options to its director, Keith Murphy. This move, filed with the SEC on November 6, 2026, is important as it aligns the interests of the company's leadership with those of its shareholders.

Background

Matinas BioPharma Holdings, Inc. operates in the pharmaceutical preparations industry, classified under SIC 2834. The company trades on the NYSE under the ticker symbol MTNB. Recent filings include multiple Form 4 submissions and an 8-K, indicating ongoing activity within the company.

What the Filing Says

The SEC filing indicates that Keith Murphy was granted an option to purchase 5,000 shares of Matinas BioPharma's common stock at an exercise price of $1.16. This option is set to vest fully either on the one-year anniversary of the grant date or upon a change in control, provided Murphy remains with the company through the vesting period.

Impact

This stock option grant may affect various stakeholders, particularly shareholders who will see a direct alignment of Murphy's interests with their own. It also reflects the company's strategy to retain key personnel in a competitive industry.

What's Next

The filing does not say what happens next.

Details of the Stock Option

The stock option granted to Keith Murphy allows him to purchase 5,000 shares of Matinas BioPharma's common stock at an exercise price of $1.16 per share. This option is part of the company's 2025 Equity Incentive Plan, which aims to incentivize and retain key personnel. The expiration date of the option is set for November 6, 2036, providing a long-term incentive for Murphy.

Vesting Conditions

The vesting of the stock option is contingent upon Murphy's continued service with the company. It will fully vest either on the one-year anniversary of the grant date or in the event of a 'Change in Control' as defined by the Plan. This structure is designed to ensure that Murphy remains committed to the company's success during this critical period.

Ownership Following the Transaction

Post-transaction, Keith Murphy will own a total of 5,000 shares of Matinas BioPharma's common stock directly. This direct ownership reflects his alignment with shareholders and commitment to the company's future performance.

Legal Representation

The filing was signed by Jerome D. Jabbour, acting as attorney-in-fact for Keith Murphy, indicating that proper legal protocols were followed in the execution of this transaction.